International Journal of Infectious Diseases
Volume 14, Issue 8 , Pages e717-e722, August 2010

Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK

  • Mark Melzer

      Affiliations

    • Department of Microbiology, Queen's Hospital, Barking, Havering and Redbridge Trust, Romford, Essex RM7 OAG, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 0 845 130 4204x3756/6251; fax: +44 0 20 8970 5784.
  • ,
  • Nidhi Gupta

      Affiliations

    • Department of Respiratory Medicine, Queen's Hospital, Romford, Essex, UK
  • ,
  • Irene Petersen

      Affiliations

    • Department of Primary Care and Population Health, University College London Medical School, London, UK
  • ,
  • Sue Cook

      Affiliations

    • Department of Respiratory Medicine, King George Hospital, Goodmayes, Essex, UK
  • ,
  • Bridget Hall

      Affiliations

    • Department of Respiratory Medicine, Queen's Hospital, Romford, Essex, UK

Received 2 June 2009; received in revised form 8 January 2010; accepted 9 February 2010. published online 14 June 2010.

Corresponding Editor: Sheldon Brown, New York, USA

Summary 

Objectives

To determine the utility of ‘risk assessment’ in selecting Mycobacterium tuberculosis isolates for rifampin resistance or rpoB genotyping compared to ‘non-selectively’ genotyping all isolates. Secondly, we examined the association between past treatment and drug resistance.

Methods

From January 2003 to December 2006, demographic, clinical, and laboratory data were prospectively collected on patients with laboratory-confirmed tuberculosis (TB). On the basis of past treatment for active TB infection or known exposure to drug-resistant TB, selected samples were sent to a mycobacterial reference laboratory for rpoB genotyping. A multivariable logistic regression model was developed to examine the association between past treatment and drug resistance, adjusted for other factors. Sensitivity, specificity, and negative and positive predictive values of past treatment as a predictor for drug resistance were determined.

Results

There were 392 patient episodes of culture-proven TB. Thirty-three drug-resistant isolates were cultured from 30 patients: 29 (87.9%) were isoniazid-resistant, three (9.1%) were multidrug-resistant (MDR), and one (3.0%) was rifampin mono-resistant. One patient with isoniazid resistance developed recurrent disease, and two isolates, initially isoniazid-resistant, mutated and became MDR TB. Based on risk assessment, rpoB genotyping was performed on 19 samples, and two (10.5%) had mutations that predicted multiple drug resistance. Although for MDR TB, a past history of treatment predicted two out of three patients with acquired resistance, adjusted analysis did not demonstrate a significant association between previous treatment of active TB and drug resistance (odds ratio 1.5, 95% confidence interval (CI) 0.4–5.6). The positive predictive value of past treatment as a predictor for drug resistance was 12.0% (95% CI 2.6–31.2%).

Conclusion

Although numbers of MDR TB were too small to draw meaningful conclusions, past treatment may be useful in selecting samples for rpoB genotyping. Overall, previous treatment had a low positive predictive value for drug resistance in an area bordering East London.

Keywords: TB, Drug resistance, Past treatment, NICE

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1201-9712(10)02351-9

doi:10.1016/j.ijid.2010.02.2247

International Journal of Infectious Diseases
Volume 14, Issue 8 , Pages e717-e722, August 2010